We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Grants Breakthrough Designation to Exelixis’ Cancer Drug Cabozantinib
FDA Grants Breakthrough Designation to Exelixis’ Cancer Drug Cabozantinib
Exelixis expects to submit an NDA by the end of this year for cabozantinib to treat advanced renal cell cancer, following the receipt of FDA breakthrough therapy designation for use in patients who have received one prior therapy.